Cidara Therapeutics, Inc. — Cyborg Score 9/10

Exceptional
Clinical-stage antiviral therapeutics

Strategic Profile

The company's proprietary Cloudbreak platform enables development of novel drug-Fc conjugates, with CD388, a long-acting antiviral for influenza prevention, earning Breakthrough Therapy designation from the FDA in October 2025. CD388 demonstrated up to 76.1% prevention efficacy in Phase 2b trials. The $9.2 billion acquisition by Merck validates the platform's potential as a game-changing antiviral technology with applications beyond influenza.

Cyborg Score Rationale

Cidara achieved the highest biotech validation—a major pharma acquisition at significant premium based on clinical potential. CD388's Breakthrough Therapy designation and Phase 2b efficacy data demonstrate strong proof-of-concept. The Cloudbreak platform enables a new drug class with broad therapeutic applications.

Top Insights

  • (November 2025) Merck acquisition announced at $221.50/share, valuing the company at ~$9.2 billion—extraordinary premium for clinical-stage biotech
  • (October 2025) CD388 received FDA Breakthrough Therapy designation, significantly accelerating development timeline
  • CD388 achieved 76.1% prevention efficacy in Phase 2b trials, positioning it as potentially first-in-class long-acting influenza antiviral
  • Cloudbreak platform generates novel drug-Fc conjugates with applications spanning antivirals, oncology, and other therapeutic areas

Named Competitors

  • Tamiflu (oseltamivir) — Neuraminidase inhibitor for seasonal influenza treatment
  • Baloxavir marboxil (Xofluza) — Cap-dependent endonuclease inhibitor for influenza
  • Infliximab-based antivirals — Broad antiviral portfolio including molnupiravir

Recent Developments

  • (November 2025) Merck agreed to acquire Cidara for $221.50 per share, total enterprise value ~$9.2 billion
  • (October 2025) CD388 received FDA Breakthrough Therapy designation
  • (2025) CD388 advanced to Phase 2b trials with significant efficacy results; partnered with Merck during active development

Open the full interactive Cidara Therapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →